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Abstract: Due to industrialization and sedentary life, incidence of type 2 diabetes (DM2) is increasing seriously. Repag-
linide is a glucose reducing agent that predominantly reduces post-prandial glucose. Continuous glucose monitoring sys-
tem (CGMS) monitors blood glucose excursions over a 3-day period. CGMS can be used as a therapeutic and diagnostic 
instrument in diabetics. There are not enough studies about using CGMS in DM2. The aim of this study was to determine 
the blood glucose excursions in patients with new onset of DM2. 10 patients with new onset of DM2 were entered to this 
study. As the first therapeutic management, patients received diabetic diet and moderate exercise for 3-weeks, if they did 
not achieve blood glucose goal (Fasting blood glucoser (FBG) <120mg/dl, 2-hour postprandial blood glucose (2hpp) 
<180mg/dl), were considered to undergo 3-days CGMS at baseline and after 4-weeks on Repaglinide (0.5mg three times 
before meals). Mean excursions of blood glucose were not different at the onset and at the end of treatment (6±4.05 VS 
7.6±5.2 episodes, P=0.49). There were also no significant differences between mean duration of hypoglycemic episodes 
(zero VS 5.1±14.1 hours, P =0.28) and hyperglycemic episodes before and after therapy (7.6±5.2 VS 5.7±4.1, P=0.42), 
but mean hyperglycemia duration was significantly reduced at the end of therapy (21±26.17 VS 57.7±35.3, P=0.001). Pa-
tients experienced a mean of 0.3±0.67 episodes of hypoglycemia after therapy showed no significant difference before it 
(P =0.19). Mean FBG (with CGMS) was significantly lower after therapy than before it (142.9±54.31 VS 222.9±82.6, P 
<0.001).  
This study showed the usefulness of CGMS not only as a diagnostic but also as an educational and therapeutic tool that in 
combination with Repaglinide (with the lowest effective dose and duration) can significantly reduce FBG and glycemic 
excursions in DM2 patients and hypoglycemic events are low. 
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INTRODUCTION 
 Type 2 diabetes mellitus (DM2) increases with age, so-
cial industrialization and sedentary life style. Some studies 
have shown postprandial hyperglycemia and glycemic ex-
cursions in DM2 which are associated with cardiovascular 
complications [1-7]. Hypoglycemia is associated more with 
old oral hypoglycemic agents such as sulfonylurea, as they 
have longer half-lives [1, 4-8]. On the other hand in spite of 
proper treatment and maximum dosage of Sulfonylurea, hy-
perglycemia (especially post-prandial) is still a problem in 
diabetic patients [1, 9, 10]. Repaglinide which mainly de-
creases postprandial blood glucose and FBG might control  
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the glycemic excursions in DM2 patients. The risk of hypo-
glycemia is lower with Repaglinide, because of shorter half-
life as compared to Sulfonylurea [9]. Repaglinide belongs to 
the Meglitinide class with benzoic acid in its structure [1]. 
This drug decreases blood glucose level by stimulating the 
release of insulin and has a short half-life. The drug, intro-
duced in 1995[4-8], is used as a second line in DM2 if the 
hyperglycemia is not controlled by other first line drugs. But 
since it has the ability to control glycemic variability via 
lowering post-prandial glucose, therefore, it can be recom-
mended to be used in DM2 as the first line treatment. In the 
present study, it has been used as a the first line drug treat-
ment for new onset of DM2 patients and their glycemic ex-
cursions have been monitored in order to investigate whether 
the drug in combination with 3 days CGMS can reduce gly-
cemic excursions in this patients group. The first continuous 
glucose monitoring system that was approved by FDA was 
MiniMed. MiniMed is continuously in contact with patient's 
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abdomen for 72 hours via a tiny glucose sensing device 
which is inserted just under the skin of patient's abdomen. 
The system automatically records an average glucose value 
every 5 minutes. During 72 hours 864 recordings prepare a 
chart showing exact monitoring of blood glucose fluctuations 
during a day, especially at times like midnight (the risk of 
hypoglycemia is more at this time). It does not provide real 
time glucose values to the patient wearing it. The data saved 
in the system during monitoring usually lasts 3 days and can 
only be downloaded by the physician. Patients can be in-
formed about their glycemic excursions, food and activities 
that have any effect on glycemic variability (as during 
CGMS monitoring patients should record the food time and 
type and also activity like exercise in a questioner). These 
observations are helpful in deciding the exact dosage, diet 
and patient's activity to control blood glucose precisely and 
prevent hypoglycemic and hyperglycemic attacks [9, 15]. It 
is approved to be used as a holter type monitoring system 
which record minutes to glycemic control in DM1 patients. 
But few studies of applying CGMS in type 2 diabetic pa-
tients have been published. The aim of this study was to de-
termine if CGMS could improve glycemic excursions in new 
onset of DM2 patients as an adjuvant to Repaglinide.  
MATERIALS AND METHODS 
 Fifteen new DM2 patients, aged between 30-60 years old 
whose FBG was ≥126mg/dl were selected. Patient's data 
such as age, height, weight, blood pressure, Body Mass In-
dex (BMI), underlying diseases and drug history were re-
corded. Fasting blood glucose (2 times tests), glycated he-
moglobin (HbA1C), blood glucose, 2-hour postprandial 
blood glucose (2hpp), urea, Creatinine, serum glutamate ox-
aloacetate transferase (SGOT) and serum glutamate pyruvate 
transferase (SGPT) were checked for all of the patients. All 
biochemical parameters were measured by commercial kit 
using spectrophotometer technique. Weight was then meas-
ured, while subjects were minimally clothed without shoes, 
using digital scales. Height was measured in standing posi-
tion without shoes using tape meter while the shoulder was 
in a normal position. Body mass index (BMI) was calculated 
as weight in kilograms divided by height in meters squared. 
Systolic and diastolic blood pressure was measured twice 
after 10-15 minutes resting in sitting position from the right 
hand]. Exclusion criteria were: renal or hepatic failure, pa-
tients that used fibrats as triglyceride lowering drugs and 
FBG ≥250mg/d. At first step, we prescribed diabetic diet and 
exercise (30 minute walking every day) for three weeks. At 
the end of 3rd week the FBG and postprandial Glucose of all 
patients were evaluated. At this stage, 4 patients whose FBG 
and postprandial glucose levels were found to be in accept-
able range were excluded from the study. The study contin-
ued with those patients whose FBG or postprandial glucose 
level was more than 120mg/dl or 180 mg/dl, respectively. 
Eleven patients were then asked to wear a continuous glu-
cose monitoring system for 72 hours. The CGMS consists of 
a glucose oxidase sensor inserted in the subcutaneous fat of 
abdominal wall, and reacts with glucose in the interstitial 
fluid. This reaction creates electronic signals and their aver-
ages were stored in the device after every 5 minutes. During 
this period, patients controlled their capillary blood glucose 
level four times a day by a Glucometer (Accue check) and 
input the data into the CGMS monitor for calibration of the 
device. All patients were also asked to record in a questioner 
the time and type of all meals and the time of exercise (30 
minutes walking a day). At the end of the third day, all the 
sensors were removed from the patients and the CGSM data 
was downloaded and glucose profiles were created for fur-
ther analysis. The CGMS glucose profiles were then re-
viewed. The patients were inquired about the affects of spe-
cial foods and walking on their glycemic variability, based 
on their CGMS profile and their records in the form of ques-
tioner on the type and time of foods and time of exercise. At 
this step, one of the patients decided to leave the study and 
the study continued with ten patients. They were prescribed 
Repaglinide 0.5 mg three times before meals. Patients were 
also asked to keep their diet and their exercises for 1 month. 
At the end of first month, their FBG and postprandial BG 
were measured for further analysis. Once again all patients 
were asked to wear CGMS for 3 more days while taking 
Repaglinide. After a 3-day period, all the sensors were re-
moved from the patients and the CGSM data were 
downloaded and glucose profiles were created for further 
analysis. Finally, their blood glucose fluctuations were com-
pared to their initial blood glucose profiles prior to the treat-
ment with Repaglinide. 
 Statistical analysis and reporting of obtained data were 
carried with the help of SPSS-16, paired student t‐test and 
Chi-Square. P-value < 0.05 was considered to be statistically 
significant. 
RESULTS 
 In the first stage, fifteen newly diagnosed type 2 diabetic 
patients were enrolled. In 4 patients, after 3 weeks of dia-
betic diet and exercise, fasting and postprandial blood sugar 
was in the normal range. Thus, they were excluded from the 
study. One patient at the first phase of the study after com-
pleting the first time CGMS (before intervention) was not 
willing to continue the study. A total of ten patients (5 male 
and 5 female) with mean ages of 45.7±6.46 year old, com-
pleted trial without withdrawal problems. Medical and drug 
histories were negative in all patients. Patient’s characteris-
tics have been summarized in Table 1. Among all patients 
that wore CGMS before and after intervention, only one pa-
Table 1. Characteristics of Diabetic Patients 
Parameters Mean  SD 
Age (year) 45.7 6.46 
BMI (kg/m2) 28.15  3.9 
Systolic Blood pressure (mmHg) 117.5  12.7 
Diastolic Blood pressure (mmHg) 78.2  7.5 
FBG (mg/dl) 174.2  26.2 
2hpp (mg/dl) 236.6  59.4 
HbA1C (%) 8.67  1.08 
Creatinine (mg/dl) 0.85  0.1 
FBG: Fasting blood glucose, BMI: Body mass index, 2hpp: 2-hour post-
prandial blood glucose and HbA1C: Glycated hemoglobin.
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tient (5%) complained of inflammation at the insertion site of 
CGMS. This situation was controlled through antibiotic. As 
shown in Tables 2 and 3, there were significant differences 
between FBS measured by laboratory and CGMS before and 
after treatment (P <0.001). The mean total blood sugar level 
(recorded by Glucometer) before intervention was signifi-
cantly higher than after the therapy (230.9±67.1 vs. 
146.5±45.9 P=0.02, t=2.58). Patients with FBG ≥ 250 mg/dl 
were excluded. According to CGMS glucose profiles, those 
patients whose BG was more than 400mg/dl in their profiles 
before intervention, showed the effectiveness of CGMS in 
detection of hyperglycemia. As shown in Table 3, reduction 
in FBG and 3hpp was significant after intervention. Blood 
sugar excursions recorded by CGMS before and after inter-
vention were shown in Table 4, and mean reduction of blood 
sugar after therapy was showed in Table 5. The mean abso-
lute differentiation between glucometer and CGMS, before 
and after intervention, was 7.97±0.3 and 10.07±3.6 percent, 
respectively. A correlation was found between glucometer 
and CGMS. The mean glucose readings during CGMS be-
fore and after intervention were 789.1±89.63 and 
855.2±134.64, respectively. Glycemic excursions defined 
through the device as hypoglycemia (<50mg/d) and hyper-
glycemia (>180mg/d) during 72 hours of CGMS before and 
after intervention were 7.6±5.2 and 6±4.5 (p-=0.49), respec-
tively. No statistical differences were found between the 
number of hyperglycemic and hypoglycemic attacks (Table 
4), but the duration of hyperglycemic episodes was signifi-
cantly reduced after intervention (21±26.1 VS 57.7±35.3 
hour, p=0.001). Patients who experienced a mean of 
0.3±0.67 episodes of hypoglycemia after therapy, did not 
show any hypoglycemic episode before intervention 
(P=0.19). 
DISCUSSION 
 In this study, we used CGMS as a monitoring system to 
detect glycemic excursions in new onset of DM2 patients 
before and after treatment with Repaglinide. The results of 
present study showed that CGMS could be a useful adjuvant 
for Repaglinide in new onset of DM2 patients. Information 
gathered through conversing with the patients about their 
glucose variability as per CGMS profiles and factors that 
may likely affect glycemic excursions (types of different 
foods, exercise) could be considered as an advantage of 
Table 2. The Glycemic Control of Parameters Measured by Laboratory and Glucometer before and after Intervention 
Parameters Baseline After Intervention P-value 
FBG* (mg/dl) 174.226.2 121.332.2 <0.001 
2-hour postprandial blood glucose* (mg/dl) 232.659.4 13541.7 <0.001 
Mean total BG **(mg/dl) 230.967.1 146.545.9 0.029 
Fasting blood glucose (FBG*) measured by laboratory, Blood glucose (BG**) measured by Glucometer. 
Table 3. Baseline and After Intervention of Glycemic Control Parameters Measured by CGMS 
Parameters Baseline After Intervention P-value 
FBG* (mg/dl) 82.6  222.9 142.954.31 <0.001 
BG* 3 hour after breakfast (mg/dl) 221.477.3 141.843.78 0.004 
BG 3 hour after lunch (mg/dl) 230.977.22 140.138.23 0.003 
BG 3 hour after dinner (mg/dl) 239.268.63 151.452.44 0.001 
Minimum BG (mg/dl) 110.867.83 66.320.76 0.109 
Maximum BG (mg/dl) 324.863.01 244.775.37 0.004 
Mean total BG (mg/dl) 20935.31 14438.13 0.01 
(BG*): Blood Glucose 
Table 4. Blood Glucose Fluctuations Recorded by CGMS Before and After Intervention 
Parameters Before Intervention After Intervention P-value 
Number of blood glucose fluctuation* 7.65.2 6.0 4.05  0.49 
Number of hypoglycemic attack 0 0.30.67 0.19 
Duration of hypoglycemic attack (hour) 0 5.114.1 0.28 
Number of hyperglycemic attack 7.65.2 5.74.1 0.42 
Duration of hyperglycemic attack (hour) 57.735.3 21.026.1 0.001 
* Number of episodes that patients’ blood glucose were out of range set by CGMS (50-180 mg/dl).
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CGMS. This study showed that Repaglinide with lowest 
therapeutic dose and duration could be effective at lowering 
2-hour postprandial blood glucose level and fasting blood 
glucose. The results of this study also displayed that rate of 
hypoglycemic events with Repaglinide were not significant. 
Although the glycemic excursions before and after drug ad-
ministration were not statistically significant, but CGMS 
findings indicated low rate and duration of excursions after 
the administration of Repaglinide. In CGMS monitoring, 
when blood glucose level exceeds out of defined range, it is 
recorded as excursion. Lower excursions do not necessarily 
represent patient's good condition, but duration of each fluc-
tuation is more valuable. Even if the BG in a patient might 
be over 200 mg/dl for entire 3 days CGMS records this as 
only one excursion. No hypoglycemic traces were found 
before intervention until it became evident within 72 hours 
after intervention. But the mean number of hypoglycemic 
events was 0.3 in every patient within 72 hours after inter-
vention. The duration of hypoglycemic events after drug 
administration was not statistically significant and valuable 
than before intervention (P= 0.28 and P = 0.42). Some other 
studies showed that the rate of hypoglycemia events in pa-
tients treated with Repaglinide was less than other hypogly-
cemic agents and placebo [10, 11]. In our study, the rate of 
hyperglycemic events before and after Repaglinide admini-
stration showed no significant differences. But the mean 
duration of hyperglycemic events after Repaglinide was 
clearly less than before it (P= 0.001). This indicates drug 
efficacy in decreased duration of hyperglycemia. This study 
also showed that the mean fasting blood glucose level after 
Repaglinide administration, was clearly less than before (P= 
0.001 and P = 0.04, respectively). The mean decreases in 
fasting blood glucose levels after Repaglinide administration 
were calculated 52 mg/dl and 80 mg/dl, when it was meas-
ured by the laboratory and CGMS, respectively. Some stud-
ies showed that Repaglinide efficacy was compared with 
placebo. The mean decrease in fasting blood glucose was 
70.2 mg/dl and 61mg/dl for Repaglinide and placebo, respec-
tively, which was obviously greater than placebo [12, 13]. 
Some other studies indicated that there was a significant de-
crease in fasting blood glucose level during Repaglinide 
treatment [10, 11, 14-17].The mean 2-h postprandial blood 
glucose level, as measured by the laboratory and CGMS, and 
3 hours after meal (breakfast, lunch and dinner), was also 
clearly decreased after Repaglinide administration. It was 
considered to be in the therapeutic range of postprandial 
blood glucose (less than 180 mg/dl). The mean decrease in 
postprandial blood glucose level, as measured by the labora-
tory (after Repaglinide administration compared with before 
it), was 97 mg/dl. The mean decreases in 3 hours postpran-
dial blood glucose level (breakfast, lunch and dinner), as 
measured by CGMS, were 79, 90 and 87 mg/dl, respectively. 
This showed a clear and significant reduction as compared 
before the treatment. In one study, Repaglinide efficacy was 
compared with placebo, the mean decrease in postprandial 
blood glucose level was 104 mg/dl which showed a signifi-
cant decrease [12]. In another study, the mean decrease in 2-
h postprandial blood glucose level was 111.6 mg/dl, which 
was significantly compared with placebo [13]. In most pre-
vious studies, Repaglinide dose and duration were more than 
our study in order to achieve the targeted fasting blood glu-
cose and postprandial [12-16]. This study suggested that 
CGMS might act as an adjuvant to control blood glucose 
level. It was found that glycemic control was better in pa-
tients who were more cooperative during and after CGMS 
application. Several studies have shown that application of 
CGMS on type 1 and 2 diabetic patients has beneficial ef-
fects in decreasing the blood glucose level. One study 
showed that 1.1% reduction in HbA1C (after 5 weeks) was 
observed only by adjusting time of insulin administration 
[18]. Several other studies have referred significant decrease 
in HbA1C in DM1, and few studies have been published 
showing the application of CGMS in DM2 [19-23]. Overall, 
in this study, patient cooperation in CGMS, middle age of 
the patients (mean age 45±6.4 years), low baseline of hyper-
glycemia (mean fasting blood glucose 174±26 mg/dl and 2-h 
postprandial 232±59 mg/dl), no history of underlying dis-
ease, and no medical treatment, have actually improved Re-
paglinide efficacy at lowering blood glucose level. On the 
other hand, racial and geographical location and diet are 
probably effective in response to Repaglinide. Since mini-
mum dose and the minimum time were applied for achieving 
therapeutic effects of the drug, Repaglinide may be used in 
lower doses as first therapeutic step for patients who have 
clinical features similar to the patients in this study. Overall, 
the results of this study indicate that Repaglinide is a safe 
and appropriate medication for decreasing blood glucose in 
newly diagnosed type II diabetic patients who having no 
underlying diseases. Moreover, it is apparent that CGMS can 
be used as an effective method in appropriate glycemic con-
trol and even as an effective adjuvant agent along with other 
medication in type 1 and 2 diabetic patients. 
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